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Background: St. John’s wort (Hypericum perforatum L.) is an herbaceous plant that is native to Europe, West Asia
and North Africa and that is recognized and used worldwide for the treatment of mild and moderate depression. It
also has been shown to be therapeutic for the treatment of burns, bruises and swelling and can be used for its
wound healing, antiviral, antimicrobial, antioxidant, analgesic, hepato-protective and anxiolytic properties. The aim
of this study was to evaluate the potential cytotoxic, mutagenic and antimutagenic action of H. Perforatum.
Methods: Meristematic cells were used as the test system for Allium cepa L., and bone marrow cells from Rattus
norvegicus, ex vivo, were used to calculate the mitotic index and the percentage of chromosomal aberration.
Statistical analysis was performed using the chi-square test.
Results: This medicinal plant had no cytotoxic potential in the vegetal test system evaluated. In the animal test
system, none of the acute treatments, including intraperitoneal gavage and subchronic gavage, were cytotoxic or
mutagenic. Moreover, this plant presented antimutagenic activity against the clastogenic action of
cyclophosphamide, as confirmed in pre-treatment (76% reduction in damage), simultaneous treatment (95%) and
post-treatment (97%).
Conclusions: Thus, the results of this study suggest that the administration of H. perforatum, especially by gavage
similar to oral consumption used by humans, is safe and with beneficial antimutagenic potential.
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Mitotic indexBackground
Hypericum perforatum L., popularly called St. John’s
wort (SJW), is a perennial herbaceous plant that has
yellow flowers and is native to Europe, West Asia and
North Africa, but was also naturalized in the Americas
and Australia. Its name refers to the period of flowering
and harvest, which takes place around St. John’s Day,
June 24. The genus Hypericum belongs to the family
Clusiaceae and contains approximately 370 species [1].* Correspondence: lisdusman@yahoo.com.br
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reproduction in any medium, provided the orIn order for the flowers and aerial parts to be suitably
used, they should both be immediately dried in a drying
chamber after harvesting to avoid degradation of their
active components [2].
Because of its broad action on the nervous system and
the positive impact on the treatment of mild to mode-
rate depression [1-4], consumption of this plant has in-
creased dramatically in recent years in several countries.
Even with the difficulty of estimating these numbers,
Linde [1] showed that more than 9.5 million packages
of SJW capsules were sold in Europe between April
2007 and March 2008. The main markets for SJW are
Germany (3.8 million), Russia (2.2 million) and Polandtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Peron et al. BMC Complementary and Alternative Medicine 2013, 13:97 Page 2 of 9
http://www.biomedcentral.com/1472-6882/13/97(1.6 million), which together represent 79% of sales in
Europe. These numbers had been higher before the im-
position of stricter standards for prescribing this medi-
cinal plant. In the United States in 2007, the market for
dietary supplements derived from SJW reached approxi-
mately 8.1 million dollars.
Many species of the genus Hypericum have medi-
cinal properties and were previously used in ancient
Greece for burns and leg pain and also for their
antidiuretic and antimalarial properties. Hypericum
species were also applied to external areas and were
recommended to be consumed with wine to combat
poisonous reptiles [5].
Currently, several species of the genus are being used
as a medicine based on knowledge gained from inves-
tigations in several countries. Thus, this genus has
healing and diuretic properties and is used to treat kid-
ney, urinary bladder, liver, and migraine issues. In
addition, it is anti-tussive and anthelmintic. This genus
also has sedative and calming effects and acts as an
antidepressant [6-8].
H. perforatum, a representative species of the genus,
has been included in traditional medicines in various
countries [9]. Decoctions of floral parts and H. per-
foratum have been used for the treatment of disorders of
the digestive tract, urinary tract, respiratory system,
heart, liver, joints and mental health [10-18]. Maury
et al. [19] identified 3-hydroxy lauric acid, which is
found in field grown H. perforatum, as having anti-
HIV activity.
The genus Hypericum has an exceptionally diverse and
complex chemical composition, and H. perforatum has
been found to contain several classes of components simi-
lar to most plants, including essential oils, flavonoids,
polyphenols, procyanidins, tannins, fenilpropanos, xan-
thones and porphyrins [20]. In addition to these compo-
nents, two classes of very active constituents were found
exclusively in this genus, floroglucinoides, which are
mainly hyperforin and adhiperforin, and naftodiantrones,
such as hypericin and pseudohipericin [21].
Hypericins and hiperforins are primarily responsible
for the antidepressant activity of SJW because they in-
hibit the transporters that recapture norepinephrine,
serotonin and dopamine that are released into the syn-
aptic cleft of neurons [22,23]. In methanolic or ethanolic
extracts of SJW, the concentration of hyperforin and
adhiperforin can reach 6%, but these concentrations
vary widely depending on the concentration of the
alcohol [1].
The flavonoid glycosides comprise the second largest
group of active metabolites in SJW and are mainly repre-
sented by rutin, hyperoside, isoquercetin and quercitrin.
These metabolites have some antidepressant proper-
ties, but most often act as co-effectors, increasing thepharmacological properties of other substances, such
as hypericins [24].
There use of medicinal plants by the world’s popula-
tion is growing. Because of the consumption of teas or
extracts of SJW for the treatment of mild and moderate
depression, or as a co-adjuvant with conventional drugs,
it is of interest to determine whether the use of this
plant has any benefit or harm at the cytological and
chromosomal levels. Studies involving the antimutagenic
potential of medicinal plants are important because
these plants can be used as a means of treatment with-
out interfering in a normal lifestyle or result in the in-
take of an excessive number of synthetic substances. The
aim of this study was to evaluate the potential cytotoxic,
mutagenic and antimutagenic/protector functions of H.
perforatum. As a test system, we used meristematic cells
from Allium cepa L. and bone marrow cells from Rattus
norvegicus, in vivo. Thus, this study stands out from pre-
viously conducted studies because of its investigation of
the antimutagenic activities of SJW against cyclophosa-
mide, a mutagenic chemotherapeutic agent.
Methods
Treatment solutions
The Hypericum perforatum L. (SJW) was extracted from
capsules (300 mg) (dried leaves and ground) added to an
excipient starch (Herbarium Lab), equivalent to 0.9 mg
(0.3%) of hipericin, and was dissolved in water at three
concentrations: 0.3, 3.0 and 30.0 mg/mL. Concentrations
were chosen based on an extrapolation of a daily dose
consumed by humans.
The cytostatic drug cyclophosphamide was diluted with
water at a concentration of 1.5 mg/mL and was used as a
positive control.
Allium cepa L. root-tip cells
The experiments were conducted using the Feulgen re-
action and Schiff ’s reagent for staining, according to the
methodology originally introduced by Levan in 1949 (in
Fiskesjö [25]).
The onion bulbs were placed for rooting in bottles
with water at room temperature and aerated in the dark.
Before each treatment, three roots were collected and
fixed (3 methanol: 1 acetic acid) to serve as control
bulbs (Co). The remaining roots were then placed in
treatment solutions with three concentrations of SJW
0.3, 3.0 and 30.0 mg/mL) for 24 hours. After the treat-
ment period, three roots were withdrawn from each
onion and fixed (Tr). The remaining roots were washed,
and the bulbs were again placed in water for 24 hours to
recover from any damage; then, the remaining roots
were removed and fixed (Re). The negative control on-
ions remained in filtered water throughout the sampling
time (CO-).
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jective) in “blind tests”. To determine the mitotic index
(MI-%), five bulbs were used in each control and treat-
ment group. One thousand cells per bulb were analyzed,
totaling 5,000 cells for the control, treatment and recov-
ery groups. Statistical analysis was performed using the
chi-square test (n = 5, α = 0.05).
Wistar rat bone marrow cells
Six Wistar rats (Rattus norvegicus), three males and
three females for each group, were obtained from the
Central Vivarium of the State University of Maringá
(UEM). Experiments were carried out using 35-day old
rats weighing approximately 100 g (bw).
Ethics statement
During the experimentation period, the animals re-
mained under controlled temperatures of approximately
25°C, with humidity at approximately 50% and with a
photoperiod of 12 hours light/dark. Furthermore, all
Ethical Principles, Protocols and Regulations on Experi-
mentation with Laboratory Animals were used according
to the standards established internationally and by the
approved project by the Institutional Ethics Committee
of State University of Maringá (UEM), the Ethics Com-
mittee on Animal Use in Experimentation (CEAE)/
UEM, following the Ethical Principles for Animal Ex-
perimentation established by the Brazilian College of
Animal Experimentation (COBEA), as well as the spe-
cific treatment and collections protocols made to chro-
mosomal aberration test.
Acute treatment (intraperitoneal and gavage)
For mutagenesis analysis, rats were treated with an intra-
peritoneal injection (0.3, 3.0 and 30.0 mg SJW/mL) or
with via gavage (3.0 and 30.0 mg SJW/mL), with 1 mL of
the water or treatment solutions/100 g bw. The animals
were euthanized 24 hours after treatments.
For antimutagenic analysis, the SJW treatment was ad-
ministered by gavage at a concentration of 30.0 mg/mL
prior to (pre-treatment), concurrent with (simultaneous
treatment) or after (post-treatment) the application of an
intraperitoneal injection of cyclophosphamide 1.5 mg/mL.
The high concentration of SJW was used in the anti-
mutagenicity tests because, in general, this treatment
has presented a lower percentage of chromosomal ab-
normalities and because the public’s increasing ex-
posure to herbal medicines warrants testing greater
amounts.
Subchronic treatment (gavage)
Wistar rats were submitted to a subchronic treatment
for seven days. Control group received 1 mL water daily
via gavage, and the treatment groups received the samequantity of SJW treatment solutions at concentrations of
0.3, 3.0 and 30.0 mg/mL.
The rats were kept in their cages, and food and water
were changed daily at the same time. On the eighth day,
the rats were euthanized.
Chromosomal aberration test
A chromosomal aberration test was performed on the
bone marrow cells from Wistar rats using the Ford and
Hamerton method [26], with some modifications. The
mitotic cells were interrupted in metaphase with the in-
traperitoneal administration of 0.5 mL/100 g bw of col-
chicine (0.16%), half an hour before euthanasia.
The analysis of the slides was performed by a light
microscope, analyzing 100 cells in metaphase per animal,
totaling 600 cells each for the control and treatment
groups. Cells were assessed for the appearance of al-
terations, such as gaps, breaks, fragments, and others.
The mitotic index (MI) for the cytotoxicity evaluation
was calculated from 5,000 cells from each sex, totaling
10,000 cells per group. The MI was calculated as a per-
centage as follows: the number of dividing cells divided
by the total number of cells present in the fields. The
statistical calculation was performed using the chi-
square test (n = 6, α = 0.05).
Results
Allium cepa L. root-tip cells
Figure 1 presents the results of the mitotic index and
shows that treatments with different SJW concentrations
at various sampling times (Co 0 h, Tr 24 h and Re 24 h)
were similar to the negative control. However, we ob-
served a significant increase (χ2 = 11.27) in the number
of dividing cells during the recovery of the group treated
with the 3.0 mg/mL concentration of SJW, from 3.3%
(Tr 24 h) to 9.4% (Re 24 h). There were also significantly
higher rates of recoveries at concentrations of 0.3 mg/mL
(χ2 = 8.78) and 30.0 mg/mL (χ2 = 3.96).
Wistar rat bone marrow cells
For all tests with bone marrow cells from Wistar rats,
no differences in the mitotic index were observed bet-
ween the control groups and the treatments with SJW
(Figure 2), demonstrating the absence of cytotoxic acti-
vity of H. perforatum. Only in the antimutagenicity test
(Figure 3) did we observe a statistically higher mitotic
index in the post-treatment group when compared with
the simultaneous treatments (χ2 = 4.48) and cyclophos-
phamide (χ2 = 4.69).
In the acute test for mutagenicity via gavage (Figure 2),
we observed a significantly higher number of chromo-
somal aberrations at the concentrations of 3.0 mg/mL
(χ2 = 34.81) and 30.0 mg/mL (χ2 = 24.01) of SJW, com-
pared to the negative control. In turn, the acute test for
Figure 1 The mean percentage and standard deviation of the mitotic index (MI) for the negative control group (CO-) and the group
treated with St. John´s Wort (SJW) at three concentrations (mg/mL). Treatment time: Control (Co) = 0 h, Treated (Tr) = 24 h, Recovery
(Re) = 24 h. * The results are statistically significant in relation to Recovery (24 h) SJW [3.0].
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showed that the lowest concentration evaluated (0.3
mg/mL) induced a statistically significant increase in
the number of chromosomal aberrations over the nega-
tive control (χ2 = 16.13). Mutagenicity was tested after
subchronic gavage (Figure 2), and the three concentra-
tions of SJW evaluated did not induce an increase in the
percentage of chromosomal aberrations compared to the
negative control. All concentrations of SJW in all treat-
ments evaluated were different than the positive control.
In the antimutagenicity test (Figure 3), simultaneous
treatment and post-treatment reduced the percentage ofFigure 2 The mean percentage and standard deviation of the mitotic
subchronic gavage and intraperitoneal treatments for the negative (C
with three concentrations of St. John´s wort (SJW) (mg/mL). * The resudamage induced by cyclophosphamide by a significant
amount (SIM - χ2 = 370.94; POST - χ2 = 714.15) when
compared to the level observed for the negative control
and for the SJW treatment alone. The pre-treatment also
significantly reduced the percentage of drug-induced
damage (PRE - χ2 = 3.13), but did not reached the values
observed in the negative control (χ2 = 53.13), which was
different from the treatment with SJW alone (χ2 = 40.50)
and also different from the simultaneous treatments
(χ2 = 13.83) and post-treatment (χ2 = 3.87).
Note that the response between the sexes in the
treated animals in these experiments was similarindex (MI) and chromosomal alteration (CA) of acute and
O-) and positive (CO+) control groups and for the group treated
lts are statistically significant in relation to CO-.
Figure 3 The mean percentage and standard deviation of the mitotic index (MI) and chromosomal alteration (CA) for the negative
(CO-) control group and the group treated with St. John´s wort [30.0 mg/mL] simultaneously (SIM), previously (PRE) and after (POST)
the application of cyclophosphamide (CP) [1.5 mg/mL]. * The results are statistically significant in relation to CO-. # The results statistically
significant in relation to CP. $ The results are statistically significant in relation to Simultaneous Treatment. & The results are statistically significant
in relation to Post-treatment. § The results are statistically significant in relation to SJW [30].
Peron et al. BMC Complementary and Alternative Medicine 2013, 13:97 Page 5 of 9
http://www.biomedcentral.com/1472-6882/13/97regarding mitotic index and percentage of chromo-
somal abnormalities.Discussion
Chromosomal aberrations have been recognized for a
long time as important biomarkers for human exposure
to genotoxic chemical agents and ionizing radiation.
Structural and numerical aberrations have been associ-
ated with poor health; for example, congenital abnormal-
ities in newborns and neoplasias in humans. The genetic
instability, or chromosomal instability, also seems to be
related to cancer, although the mechanisms involved in
this process are not yet fully elucidated.
The interest in organic extracts of medicinal plants or
parts of the plants, such as SJW, has increased because
these extracts are relatively safe to use, show a good ac-
ceptance among consumers and can possibly be used for
many different functions [5].
The results of this study indicate that SJW has no
cytotoxic effect on the root meristematic cells of A. cepa
and no effect on bone marrow cells from Wistar rats. In
the vegetal system (Figure 1), we observed that at all
concentrations tested, H. perforatum caused no signifi-
cant decrease in cell division after 24 hours of treatment.
However, after the recovery treatment with a concentra-
tion of 3.0 mg/mL of SJW, there was increased cellular
proliferation, which was statistically significant with re-
spect to treatment with SJW alone and the recoveries of
the other treatments. This finding indicates that despite
the inhibition of cell division to less than half comparedto control (8.3 to 3.3), the cells recovered to a division
index greater (9.4) than that obtained for the control (8.3).
Other studies have also shown that SJW or its compo-
nents can reduce cell divisions. Schempp et al. [27] de-
termined that hyperforin, a major constituent of SJW,
inhibits the proliferation of epithelial cells and human
peripheral blood mononuclear cells, even when stimu-
lated by phytohemagglutinin. Hyperforin also inhibited
the growth of autologous breast cancer cells, MT-450, in
Wistar rats in vivo [28]. In this respect, the inhibitory ef-
fect of cell proliferation in cancer cells is a major benefit
of this medicinal plant. Alecu et al. [29], Patocka [30],
Kusari et al. [31] and Xu and Leung [32] also demon-
strated that hypericin, another important component of
SJW, inhibited the growth of glioma cells in vitro and
was also capable of inducing cell death through the in-
hibition of protein kinase C (PKC), which regulates the
formation and growth of tumors.
The anti-proliferative action of crude methanol ex-
tracts of H. caprifoliatum, H. carinatum, H. connatum,
H. myrianthum, H. polyanthemum and H. ternum have
been confirmed in two cell lines, cells of human colon car-
cinoma and lung carcinoma [33]. Other anti-proliferative
activities of the methanol extract of H. perforatum have
been observed in leukemic cells (K562 and U937), human
colon carcinoma (HT-29) and cell lung carcinoma (H-
460) [33,34]. Compounds isolated from H. chinense have
demonstrated enhanced cytotoxicity against human can-
cer cell lines, including multidrug resistant cells [35,36].
Otogirone and erectquione B chloroform extracts from
whole plants of H. erectum have been shown to inhibit the
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falciparum [37].
In the Wistar rat test system (Figure 2), after acute or
subchronic gavage, SWJ was not cytotoxic, but there was
no significant increase of cell division. After intraperi-
toneal treatment, there was no statistically significant
decrease in the rate of cell division, similar to what hap-
pened in the plant test system. There was no cytotoxic
activity of H. perforatum in mammals. Similar to the
data in the present study, and the results presented in
the revised work of Hammerness et al. [38], SJW showed
no toxic effects at doses up to 5,000 mg/kg in mice and
rats. Additionally, in rats and dogs, there were only non-
specific symptoms, such as weight loss, in long-term
studies.
Other studies have also shown no harmful action of
SWJ in subchronic treatment. Rayburn et al. [39] sho-
wed that prenatal exposure to a therapeutic dose of SJW
caused no deficit in long-term behavioral tasks in the
offspring of mice. Rayburn et al. [40] also indicated that
maternal administration of SJW before and during preg-
nancy did not affect the growth or physical maturation
of the progeny of exposed rats.
Evaluation of the mutagenic activity of SJW in this study
showed that this plant had no mutagenic potential in
subchronic gavage treatments (0.3, 3.0 and 30.0 mg/mL)
(Figure 2). The acute gavage treatments (3.0 and
30.0 mg/mL) with SJW were mutagenic, as evidenced
by the fact that their mutagenicity was significantly dif-
ferent from the negative control. Although the percent-
age of chromosomal alteration due to these treatments
was very low ([3.0] = 0.6% and [30] = 0.5%), and the per-
centage of abnormalities compared to the negative con-
trol was practically nil (0.01%).
In a previous study, an aqueous ethanolic extract of
Hypericum also showed no genotoxicity in vitro, using
Chinese hamster embryo cells and hypoxanthine guan-
idine phosphoribosyl transferase, DNA synthesis and cell
transformation assays, or in vivo, by spot tests in mice
and chromosome aberration assays [41]. Ndhlala et al.
[42] determined that H. aethiopicum was not mutagenic
by the Ames test with Salmonella typhimurium, and
they found that it had antifungal activity against Can-
dida albicans.
These data also corroborate the work of Miadokova
et al. [43]. Using different test systems to evaluate the ef-
fect of hypericin, an isolated compound of SJW, they
also found no genotoxicity or antigenotoxicity activities
for this substance in the Ames test. When Saccharomy-
ces cerevisiae was used for testing, no increase in the
number of mitotic crossovers or point mutations was
observed, and there was no difference in the frequency
of structural chromosome aberrations in three cell lines
(HepG2, V79 and VH10).The negative results for the mutagenicity of sub-
chronic treatments of SJW agree with the lack of effect
on fertility, reproduction, teratogenesis and mutagenesis
with doses of up to 300 mg Hypericum/kg in rats and
dogs, which were presented by Alonso [44]. This finding
was similar to those using a 30.0 mg dose of SJW/100 g
weight in Wistar rats in the present study.
Regarding the evaluation of mutagenic activity of in-
traperitoneally injected SJW (Figure 2), the results of this
study indicate that the concentrations of 3.0 and 30.0
mg/mL were not mutagenic. It is noteworthy that the
lowest concentration of SJW (0.3 mg/mL) showed a per-
centage of chromosomal abnormalities that was signifi-
cantly different from the negative control (CO- = 0.3%
and [0.3] = 2.5%). Nevertheless, this percentage of chro-
mosomal abnormalities was low (2.5%) considering that
the percentage of basal changes in rats is 2%.
However, this percentage of aberrations (2.5%) in the
intraperitoneal test ([0.3]) was the highest among all
tests with SJW, either by gavage or intraperitoneal injec-
tion. In this regard, it can be noted that intraperitoneal
administration has a rapid absorption rate due to the
large absorptive surface of the abdominal cavity [45].
Thus, the SJW quickly runs through the bloodstream
and acts on the bone marrow, resulting in greater dam-
age to DNA. Moreover, this fact can be confirmed by
comparing the mitotic index of SJW treatment with in-
traperitoneal administration (IM [0.3] = 1.15, [3.0] = 0.67,
[30] = 0.91) to treatment by gavage; the cells were more
affected by injection of SJW rather than administration
by gavage (acute MI [3.0] = 2.0 and [30] = 1.78; sub-
chronic IM [0.3] = 1.4, [3.0] = 1.4 and [30] = 2.1). In the
administration by gavage, similar to oral ingestion in
people, the compound enters the portal circulation and
passes through the liver, where it can be metabolized
[45] and may have its cytotoxicity/mutagenicity decreased,
and then affects the bone marrow. Thus, the higher num-
ber of chromosomal alterations observed with treatment
with an intraperitoneal injection of H. perforatum may be
due to the presence of secondary metabolites, such as
quercetin, which may be responsible for the genotoxic ac-
tivity of SJW in Salmonella typhimurium [38,46].
The anticancer properties of SJW have become the
focus of many studies because many cancer patients
were, are using extracts from this plant for the treatment
of depressive symptoms developed with the discovery of
disease [21]. Thus, the study of the antimutagenic activ-
ity of this substance is as important as the study of the
anti-proliferative effect; however, the scientific literature
does not contain many studies describing the antimutage-
nic properties of SJW or its components.
In an antimutagenicity test (Figure 3), the results sho-
wed that SJW was antimutagenic, reducing the percent-
ages of chromosomal alteration due to cyclophosphamide
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eous treatment (1.1%) and 97% by post-treatment (0.6%).
The negative control was statistically similar to SJW treat-
ment alone, post-treatment and simultaneous treatment.
The potential antimutagenic effects (>75%) of dianthrone
rich acetone and aqueous methanol extracts of the aerial
flowering parts of H. perforatum have also been tested
against 2-aminofluorene, similar to the present study, by
the Ames Salmonella histidine reversion assay, with TA98
and TA100 strains of Salmonella typhimurium [47]. Simi-
lar results were also obtained using the green alga
Chlamydomonas reinhardtii, which was not mutagenic
and reduced toxicity and mutagenicity induced by methyl
methane sulfonate [43].
Bhatia et al. [47] suggested that H. perforatum, because
of its antimutagenic property, can be beneficial for the
prevention of cancer. Schwarz et al. [48] also found that
a commercial preparation of an extract from H.
perforatum, the isoform CYP1A1, showed anticancer po-
tential by serving as a potent inhibitor of a key enzyme
activator of procarcinogens in humans.
The antimutagenic activity of SJW may be due to the
combined action of its components, especially hypericin,
hyperforin and phenolic compounds. As indicated by
Hostanska et al. [49], in tests of anticarcinogenic proper-
ties, many act in a synergistic manner (e.g., hypericin
and hyperforin) by exerting anti-proliferative activity.
Many components also have cytostatic and apoptotic ac-
tivities (phenolic compounds) on cells whose genetic
material has been severely compromised by the clasto-
genic action of cyclophosphamide, as indicated by a
smaller number of chromosomal damages observed in
the metaphases analyzed. According to Theodossiou
et al. [50], hypericin is phototoxic and has an intricate
mechanism involving key proteins, vital enzymes, organ-
elle membranes and changes in cellular homeostasis that
can lead to cell death, which occurs mainly by the induc-
tion of apoptosis and/or necrosis.
The post-treatment mechanism of action occurs when
the antimutagenic substance acts upon the process that
induces the formation of mutations or the process that
repairs DNA damage [51-53].
Furthermore, Bhatia et al. [47] also justified the an-
timutagenic activity of extracts of H. perforatum by the
presence of phenolic compounds in the plant. These
compounds, and, consequently, the high antioxidant ac-
tivity of these extracts, can interfere with the metabolic
activation of pro-mutagens and can act as a blocking
agent, forming adducts with final mutagens. H. per-
foratum can also interact with the active groups of
mutagens, can protect the sites in DNA that would be
affected by the agent, or promote the capture of free
radicals [54]. This mechanism, called desmutagen, can
be simultaneously tested. Thus, in the present study, theantimutagenic activity of H. perforatum (95%) on cells
that have been treated with cyclophosphamide simultan-
eously may be explained by the fact that SJW acts dir-
ectly on the compounds that induce mutations in DNA,
inactivating them chemically or enzymatically, and may
inhibit the metabolic activation of pro-mutagenic or may
scavenge reactive molecules, as explained by Kada et al.
[51] and Kuroda et al. [53].
The protective activity of SJW was also confirmed by
Jang et al. [55], using an inducer of cellular damage,
hydrogen peroxide (H2O2). Human neuroblastoma cells
pre-treated with SJW prior to H2O2 exposure showed a
decreased occurrence of apoptotic features and inhibited
an H2O2-induced increase in caspase-3 enzyme acti-
vity. Moreover, the pretreatment of PC12 cells with a
flavonoid-rich extract of H. perforatum (FEHP) prior to
H2O2 exposure elevated the cell viability, decreased the
levels of lactate dehydrogenase release and decreased the
occurrence of apoptotic cells. Additionally, the intensity
of H2O2-induced DNA laddering was inhibited in a
dose-dependent fashion by a DNA fragmentation assay
[56]. These results suggested that FEHP might be useful
in the treatment of oxidative stress-related neurodegener-
ative diseases, such as Parkinson’s disease and Alzheimer’s
disease.
Furthermore, An et al. [57] also showed that 1,3,5,6-
tetrahydroxyxanthone and I3, II8-biapigenin, isolated
from the methanolic extract of the whole plant of H.
erectum, had moderate hepatoprotective activity against
tacrine-induced cytotoxicity in HepG2 cells.
Conclusions
The results of this study indicate that H. perforatum is
not cytotoxic or mutagenic at the times, concentrations
and types of treatments studied. Thus, it does not appear
to be harmful to the cells of organisms that have been
exposed to it. Furthermore, this plant showed antimu-
tagenic properties against the chemotherapeutic drug
cyclophosphamide, suggesting that in addition to the
medicinal properties shown in several other studies, it
also has a protective effect on the DNA within the bone
marrow cells of treated rats. Future studies should be
conducted to investigate whether SJW interferes with
the effectiveness of cyclophosphamide chemotherapy.
Thus, H. perforatum could be indicated as an anti-
depressant and could be protective for those individuals
undergoing treatment with cyclophosphamide.
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